ADAPTATION OF IMPLANT’S SURFACE TO RECIPIENT’S BODY
The proposed substance increases bio-compatibility of implants and facilitates their grafting in recipient body. Also the substance modifies the exterior and interior surface of the implant and protects donor's cells, retards the process of implant rejection by diminishing the possibility of accumulation of the free radicals that can result in mutagen changes in cells, and sustains pH required by physiological processes. The substance provides termination of recruiting by the implant surface the lymphocytes and macrophages that actively participate in the processes of inflammation and fibrous tissue formation around the implant. The substance can be applied in cell therapy, in transplantation of cells and tissues, in the processes of plasma sorption, lymph sorption and hemosorption.
TECHNOLOGY (INVENTION) DESCRIPTION:
The assigned task is solved owing to proper composition of the substance enhancing biocompatibility of implants with recipient body, which contains recipient serum albumin and, also, additionally contains amino acids,; sodium chloride; water - in amount required for bringing the volume to 1 litre, with osmomolarity 280 - 310 mOsm/l. Method of preparation of the substance for enhancement of implant biocompatibility with recipient body, which includes mixing of the components. The invention allows modification of the implant surface by the substance influencing in such a way the donor transplant/implant of either organic, or inorganic, nature that thereafter the latter is perceived as native by the relevant components of immune system.
ADVANTAGES OVER EXISTING SOLUTIONS:
The invention allows modification of the implant surface by the substance influencing in such a way the donor transplant/implant of either organic, or inorganic, nature that thereafter the latter is perceived as native by the relevant components of immune system. There are many firms that produce different kinds of artificial coatings for implants in order to prevent complications in the postoperative period. In turn, the technology we offer EP2709684A1 European Patent Office is not used.
DEVELOPMENT STATUS (STAGE):
Preclinical trials on animals (rabbits) were performed. Repeated (additional) animal studies are proposed.
IP PROTECTION STATUS:
Substance enhancing biocompatibility of implants with recipient body and method of its preparation. EP2709684A1 - EPO.
TECHNOLOGY / IP OWNERS :
Application filed by Co Ltd "Mabela", CO Ltd MABELA
More information is available upon signing a CDA / NDA (Confidential Disclosure Agreement / Non-Disclosure Agreement)